AU2010260244B2 - Disubstituted phthalazine hedgehog pathway antagonists - Google Patents

Disubstituted phthalazine hedgehog pathway antagonists Download PDF

Info

Publication number
AU2010260244B2
AU2010260244B2 AU2010260244A AU2010260244A AU2010260244B2 AU 2010260244 B2 AU2010260244 B2 AU 2010260244B2 AU 2010260244 A AU2010260244 A AU 2010260244A AU 2010260244 A AU2010260244 A AU 2010260244A AU 2010260244 B2 AU2010260244 B2 AU 2010260244B2
Authority
AU
Australia
Prior art keywords
cancer
methyl
pharmaceutically acceptable
acceptable salt
compound according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2010260244A
Other languages
English (en)
Other versions
AU2010260244A1 (en
Inventor
Philip Arthur Hipskind
Bharvin Kumar Patel
Wilson (Nee Takakuwa), Takako
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of AU2010260244A1 publication Critical patent/AU2010260244A1/en
Application granted granted Critical
Publication of AU2010260244B2 publication Critical patent/AU2010260244B2/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Peptides Or Proteins (AREA)
AU2010260244A 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists Ceased AU2010260244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21862809P 2009-06-19 2009-06-19
US61/218,628 2009-06-19
PCT/US2010/038568 WO2010147917A1 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Publications (2)

Publication Number Publication Date
AU2010260244A1 AU2010260244A1 (en) 2012-01-19
AU2010260244B2 true AU2010260244B2 (en) 2013-09-05

Family

ID=42332981

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2010260244A Ceased AU2010260244B2 (en) 2009-06-19 2010-06-15 Disubstituted phthalazine hedgehog pathway antagonists

Country Status (36)

Country Link
US (2) US8273742B2 (e)
EP (1) EP2443104B1 (e)
JP (1) JP5596139B2 (e)
KR (1) KR101389165B1 (e)
CN (1) CN102459233B (e)
AR (1) AR077014A1 (e)
AU (1) AU2010260244B2 (e)
BR (1) BRPI1011601A2 (e)
CA (1) CA2764542C (e)
CL (1) CL2011003147A1 (e)
CO (1) CO6480932A2 (e)
CR (1) CR20110658A (e)
DK (1) DK2443104T3 (e)
DO (1) DOP2011000386A (e)
EA (1) EA019059B1 (e)
EC (1) ECSP11011541A (e)
ES (1) ES2409054T3 (e)
HK (1) HK1164872A1 (e)
HN (1) HN2011003139A (e)
HR (1) HRP20130408T1 (e)
IL (1) IL216599A (e)
JO (1) JO2931B1 (e)
MA (1) MA33363B1 (e)
MX (1) MX2011014029A (e)
MY (1) MY156667A (e)
NZ (1) NZ596882A (e)
PE (1) PE20121050A1 (e)
PL (1) PL2443104T3 (e)
PT (1) PT2443104E (e)
SG (1) SG177289A1 (e)
SI (1) SI2443104T1 (e)
TN (1) TN2011000627A1 (e)
TW (1) TWI385165B (e)
UA (1) UA106755C2 (e)
WO (1) WO2010147917A1 (e)
ZA (1) ZA201108587B (e)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA102250C2 (ru) * 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
JP2012507535A (ja) * 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
KR101335770B1 (ko) * 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer
WO2012127441A1 (en) 2011-03-23 2012-09-27 Semorex Technologies Ltd. Treatment of proliferative disorders with a chemiluminescent agent
GB201309508D0 (en) * 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
US9814703B2 (en) 2013-11-14 2017-11-14 The Board Of Trustees Of The Leland Stanford Junior University Methods for treating cancer by activation of BMP signaling
CN105017140B (zh) * 2014-04-28 2017-12-29 复旦大学 邻氨基苯甲酰胺化合物及其制备方法和用途
GB2528298A (en) * 2014-07-16 2016-01-20 Redx Pharma Plc Compounds
CN105985319B (zh) * 2015-02-11 2019-02-26 复旦大学 芳基酞嗪化合物及其制备方法和用途
CN105985321B (zh) * 2015-02-11 2018-10-26 复旦大学 吡唑酞嗪化合物及其制备方法和用途
CN105985320B (zh) * 2015-02-11 2018-10-26 复旦大学 苄基酞嗪化合物及其制备方法和用途
MX2017015681A (es) 2015-06-04 2018-09-11 Pellepharm Inc Formulaciones topicas para suministrar compuestos inhibidores de hedgehog y uso de los mismos.
WO2016196879A1 (en) * 2015-06-05 2016-12-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
EA201892075A1 (ru) 2016-03-15 2019-04-30 Оризон Дженомикс, С.А. Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
CN106279114B (zh) * 2016-08-04 2019-01-29 东南大学 一种Taladegib的合成方法
US10548908B2 (en) * 2016-09-15 2020-02-04 Nostopharma, LLC Compositions and methods for preventing and treating heterotopic ossification and pathologic calcification
CN106831718B (zh) * 2016-12-30 2019-05-07 上海科技大学 平滑受体配体及其应用
WO2018211007A1 (en) 2017-05-18 2018-11-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of mast cell diseases
KR20230031285A (ko) 2020-06-26 2023-03-07 라퀄리아 파마 인코포레이티드 레티노이드와 암 치료제의 병용 요법이 효과적인 암 환자를 선별하는 방법 및 레티노이드와 암 치료제의 병용 의약
KR20230107568A (ko) * 2020-10-13 2023-07-17 엔데버 바이오메디신스, 인크. 섬유증 치료 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2009002469A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN148482B (e) 1977-06-03 1981-03-07 Pfizer
AU717744B2 (en) 1996-01-15 2000-03-30 Janssen Pharmaceutica N.V. Angiogenesis inhibiting pyridazinamines
JP5067986B2 (ja) 1998-04-09 2012-11-07 ジョンズ ホプキンズ ユニヴァーシティー スクール オブ メディシン ヘッジホッグシグナリング経路の阻害剤としてのステロイドアルカロイド誘導体の使用
ATE283700T1 (de) 1999-06-08 2004-12-15 Lorantis Ltd Therapeutische verwendung eines inhibitors des hedgehog signalübertragungsweges
BR0211513A (pt) * 2001-07-27 2005-08-30 Curis Inc Mediadores de caminhos sinalizantes de hedgehog, composições e usos relacionados ao mesmo
WO2004020599A2 (en) 2002-08-29 2004-03-11 Curis, Inc. Hedgehog antagonists, methods and uses related thereto
US8067608B2 (en) 2003-09-29 2011-11-29 The Johns Hopkins University Hedgehog pathway antagonists
TW200533356A (en) 2004-02-24 2005-10-16 Mitsubishi Pharma Corp Fused pyridazine derivatives
EP1745039A4 (en) 2004-05-08 2009-07-22 Neurogen Corp 3-ARYL-5,6-DISUBSTITUTED PYRIDAZINES
KR20150090263A (ko) 2004-09-02 2015-08-05 제넨테크, 인크. 헤지호그 신호전달에 대한 피리딜 억제제
EP1900731A1 (de) * 2006-09-07 2008-03-19 Bayer Schering Pharma Aktiengesellschaft N-(1-Phthalazin-1-yl-piperidin-4-yl)-amide als EP2-Rezeptor Modulatoren
US8222251B2 (en) 2007-09-07 2012-07-17 Amgen Inc. Pyridopyridazine compounds, compositions and methods of use
BRPI0820856A2 (pt) * 2007-12-13 2019-05-14 Siena Bhiotech.S.P.A. anatagonista da série de reação de hedgehog e aplicações terapêuticas dos mesmos
UA102250C2 (ru) 2008-04-29 2013-06-25 Эли Лилли Энд Компани Двухзамещенные фталазины - антагонисты проводящего пути hedgehog
US20100041663A1 (en) 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
EP2321298B1 (en) * 2008-08-04 2013-10-02 Amgen Inc. Aurora kinase modulators and methods of use
JP2012507535A (ja) 2008-11-03 2012-03-29 イーライ リリー アンド カンパニー 二置換フタラジンヘッジホッグ経路アンタゴニスト
KR101335770B1 (ko) 2008-11-17 2013-12-12 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
KR101342184B1 (ko) 2008-11-17 2013-12-19 일라이 릴리 앤드 캄파니 사치환된 피리다진 헷지호그 경로 길항제
AR077014A1 (es) 2009-06-19 2011-07-27 Lilly Co Eli Compuesto derivado de ftalazina 1,4-disustituida, composicion farmaceutica que lo comprende y uso para preparar un medicamento util para el tratamiento de cancer

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003088970A2 (en) * 2002-04-22 2003-10-30 Johns Hopkins University School Of Medicine Modulators of hedgehog signaling pathways, compositions and uses related thereto
WO2008110611A1 (en) * 2007-03-15 2008-09-18 Novartis Ag Organic compounds and their uses
WO2009002469A1 (en) * 2007-06-25 2008-12-31 Amgen Inc. Phthalazine compounds, compositions and methods of use

Also Published As

Publication number Publication date
DOP2011000386A (es) 2012-02-29
HK1164872A1 (en) 2012-09-28
AR077014A1 (es) 2011-07-27
EP2443104B1 (en) 2013-04-17
PL2443104T3 (pl) 2013-08-30
US20120316174A1 (en) 2012-12-13
US20100324048A1 (en) 2010-12-23
ES2409054T3 (es) 2013-06-24
CO6480932A2 (es) 2012-07-16
JP5596139B2 (ja) 2014-09-24
EP2443104A1 (en) 2012-04-25
TW201113268A (en) 2011-04-16
MX2011014029A (es) 2012-02-21
PT2443104E (pt) 2013-05-07
PE20121050A1 (es) 2012-08-09
CA2764542C (en) 2013-09-10
UA106755C2 (uk) 2014-10-10
KR20120024783A (ko) 2012-03-14
CN102459233B (zh) 2014-07-02
HRP20130408T1 (en) 2013-06-30
BRPI1011601A2 (pt) 2016-03-22
US8273742B2 (en) 2012-09-25
MA33363B1 (fr) 2012-06-01
SG177289A1 (en) 2012-02-28
SI2443104T1 (sl) 2013-07-31
TWI385165B (zh) 2013-02-11
AU2010260244A1 (en) 2012-01-19
CN102459233A (zh) 2012-05-16
HN2011003139A (es) 2013-07-29
KR101389165B1 (ko) 2014-04-24
JO2931B1 (en) 2015-09-15
IL216599A (en) 2015-09-24
JP2012530705A (ja) 2012-12-06
WO2010147917A1 (en) 2010-12-23
EA201270049A1 (ru) 2012-05-30
TN2011000627A1 (en) 2013-05-24
ECSP11011541A (es) 2012-01-31
NZ596882A (en) 2013-08-30
MY156667A (en) 2016-03-15
CL2011003147A1 (es) 2012-07-20
EA019059B1 (ru) 2013-12-30
IL216599A0 (en) 2012-03-01
ZA201108587B (en) 2013-05-29
US9000023B2 (en) 2015-04-07
DK2443104T3 (da) 2013-05-06
CA2764542A1 (en) 2010-12-23
CR20110658A (es) 2012-02-20

Similar Documents

Publication Publication Date Title
AU2010260244B2 (en) Disubstituted phthalazine hedgehog pathway antagonists
JP5518887B2 (ja) 四置換ピリダジンヘッジホッグ経路アンタゴニスト
CA2742539C (en) Disubstituted phthalazine hedgehog pathway antagonists
MX2010011948A (es) Antagonistas de la trayectoria hedgehog de ftalazina disustituida.
ES2446307T3 (es) Piridazinas tetrasustituidas antagonistas de la ruta de Hedgehog

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired